
        <!DOCTYPE html>
        <html>
        <head>
            <title>OCR Results - 3102_phase2_dose_optimization.jpg</title>
            <style>
                body { 
                    font-family: Arial, sans-serif; 
                    margin: 0; 
                    padding: 20px; 
                    background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
                }
                .container {
                    max-width: 1200px;
                    margin: 0 auto;
                    background: white;
                    border-radius: 10px;
                    overflow: hidden;
                    box-shadow: 0 10px 40px rgba(0,0,0,0.2);
                }
                .header {
                    background: #2d3748;
                    color: white;
                    padding: 30px;
                }
                .stats {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
                    gap: 20px;
                    padding: 30px;
                    background: #f7fafc;
                }
                .stat-card {
                    background: white;
                    padding: 20px;
                    border-radius: 8px;
                    text-align: center;
                    box-shadow: 0 2px 4px rgba(0,0,0,0.1);
                }
                .stat-value {
                    font-size: 36px;
                    font-weight: bold;
                    color: #667eea;
                }
                .stat-label {
                    color: #718096;
                    margin-top: 5px;
                }
                .content {
                    padding: 30px;
                }
                .text-preview {
                    background: #f7fafc;
                    padding: 20px;
                    border-radius: 8px;
                    font-family: monospace;
                    font-size: 14px;
                    max-height: 500px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                }
            </style>
        </head>
        <body>
            <div class="container">
                <div class="header">
                    <h1>OCR Processing Complete!</h1>
                    <p>File: 3102_phase2_dose_optimization.jpg</p>
                    <p>Processed: 2025-10-31 19:58:39</p>
                </div>
                
                <div class="stats">
                    <div class="stat-card">
                        <div class="stat-value">15,575</div>
                        <div class="stat-label">Characters</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2,883</div>
                        <div class="stat-label">Words</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">137</div>
                        <div class="stat-label">Lines</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">Tesseract</div>
                        <div class="stat-label">OCR Engine</div>
                    </div>
                </div>
                
                <div class="content">
                    <h2>Extracted Text Preview</h2>
                    <div class="text-preview">M = T H O D S Figure 1. Study Design
a ; INT a ION This multicohort phase I/II trial, evaluated the safety and efficacy of Diseaseapecilic eolinte® ; n i i ‘ |
her Linda R Duska | LRD @uvahealth g pn a re conte tulmimetostat. The two cohorts presented here evaluated tulmimetostat as lexcres ans) Mt vort)
‘ monotherapy in patients with AR/D1Amut OCCC (Cohort M2) or EC (Cohort M3) | .
ee i ; The patients received one of the following three doses (Figure 1): | ve | Ss Se ee stage’: Sige
C rites 7 . im n=10 plus n=19
: : . : splays p a poorer fel r survival ! ne npared red to other e : : 350 ; ; i j x5 EC: endometrial carcinomat 200 mg: n=10 200 mg: n=10
_ mg continuous once daily (OD) dose in a dose expansion stage & : endometrial carcinoma per cohort except per cohort Close RP2D ig Dose ig.
P h ase | | d ose O ti Mmiz ati on sore OCs in reins mea waar ot pore ; Seog cetnuats nee ay Gn) oes p g as | w | enon contaniceen ee option =
h h yo HESS |P 2 g 3 9 SE SAFIVORR dose optimization 300 mg: n=10 expansion in 300 mg: n=10
. = i i 2 in M2/M3 cohort
. : : : a on To evaluate an optimal dose of tulmimetostat monotherapy, the phase II i in cohorts per cohort M2/M3 cohorts per cohort
d t th E 7 \-| 2/E 71H | h b t | Si ‘ave ARTO rt Fists oe th study design was updated to assess two additional doses of 300 mg and hi
u p rs | e WI | n | | O r 200 mg continuous OD dose * & fs Sank P
. ag ‘tage 2b initiates once either of the Stage 2a
oO * Dose optimization was conducted in two stages, Stage 2a and Stage 2b. a C predefined protocol criteria’ are met
tu | m ] m etostat D 7 R1 23/C P| -0209 In each cohort, Stage 2a comprises 20 patients, randomized 1:1 between 1. 22/10 ORR in a dose cohort
200 mg and 300 mg; Stage 2b enrolled up to 20 more patients in each cohort if 2. 1/10 ORR in a specific cohort
“ . a predefined protocol conditions were met in Stage 2a (Supported by totality of data)
] n pat ] e n ts with ARID 1A =“—MN u tated + Key eligibility criteria included adult patients with disease who had progressed $ SO ere meee mascked and
d lymphomas. na MW on applicable prior lines of treatment and met other tumor-specific inclusion (supported by totality of data)
+ = expansion and ele Ualas pempiotocolgand aellsted On) |nicalinalidoy *Patients in all cohorts have progressive disease with applicable prior lines of therapy; ‘Histologically or cytologically confirmed progressive tumor; Including GCB-DLBCL; *Stage 2b enrollment will be initiated if criterion in Stage 2a are
Ov rs | a rs | n Cc ea r ce Cc rs | rc ] n (@) Mm rs | (@) r . Primary endpoint was objective response rate (ORR) and secondary endpoint met as follows: Criteria 1 is met (22 responses in a dose cohort), or Criteria 2 is met (21 response in a specific dose cohort). Stage 2b enrollment may be initiated based on totality of safety, efficacy, and exposure-response data of that
cohort; or if Criteria 3 is met (no response in 300 mg cohort and 22/10 ORR in 200 mg cohort). Stage 2b may be opened for t...</div>
                </div>
            </div>
        </body>
        </html>
        